Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of highly active RRMS according to McDonald criteria (2018) and initiating natalizumab treatment is indicated based on current summary of product characteristics (SmPC)
In RRMS participants who are already on natalizumab therapy, continued treatment must be indicated based on current SmPC
You may not be if
Progressive forms of MS
Contraindication to natalizumab treatment according to natalizumab SmPC
Concomitant treatment with other drugs for treating RRMS
